The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis

Great starting point for anyone working on drugs with a plateau effect in survival, and who is new to the fragility index but affected by questions of statistical power and the tail of the Kaplan-Meier curve.